United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - ezogabine (unii: 12g01i6bbu) (ezogabine - unii:12g01i6bbu) - ezogabine 50 mg - potiga® is indicated as adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments and for whom the benefits outweigh the risk of retinal abnormalities and potential decline in visual acuity [see warnings and precautions (5.1)] . none. pregnancy category c. there are no adequate and well-controlled studies in pregnant women. potiga should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in animal studies, doses associated with maternal plasma exposures (auc) to ezogabine and its major circulating metabolite, n-acetyl metabolite of ezogabine (namr), similar to or below those expected in humans at the maximum recommended human dose (mrhd) of 1,200 mg per day produced developmental toxicity when administered to pregnant rats and rabbits. the maximum doses evaluated were limited by maternal toxicity (acute neurotoxicity). treatment of pregnant rats with ezogabine (oral doses

United States - English - NLM (National Library of Medicine)

wg critical care, llc - penicillin g potassium (unii: vl775zth4c) (penicillin g - unii:q42t66vg0c) - penicillin g 1000000 [iu] - therapy: penicillin g potassium for injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin g. therapy with penicillin g potassium for injection, usp may be indicated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. clinical indication infecting organism septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis streptococcus pyogenes (group a β-hemolytic streptococcus), other β-hemolytic streptococci including groups c,h,g,l and m, streptococcus pneumoniae and staphylococcus species (non-penicillinase producing strains) anthrax bacillu

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - penicillin g potassium (unii: vl775zth4c) (penicillin g - unii:q42t66vg0c) - penicillin g 3000000 [iu] in 50 ml - penicillin g potassium injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin g. therapy with penicillin g potassium injection, usp may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. clinical indication infecting organism septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis streptococcus pyogenes (group a β-hemolytic streptococcus), other β-hemolytic streptococci including groups c, h, g, l and m, streptococcus pneumoniae and staphylococcus species (non-penicillinase producing strains) anthrax bacillus anthrac

United States - English - NLM (National Library of Medicine)

sandoz inc - penicillin g potassium (unii: vl775zth4c) (penicillin g - unii:q42t66vg0c) - penicillin g 5000000 [iu] - buffered penicillin g potassium for injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin g. therapy with buffered penicillin g potassium for injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis streptococcus pyogenes (group a beta-hemolytic streptococcus ), other beta-hemolytic streptococci including groups c, h, g, l and m, streptococcus pneumoniae and staphylococcus species (non-penicillinase producing strains) anthrax bacillus anthracis actinomycosis (cer

United States - English - NLM (National Library of Medicine)

king bio inc. - official hpus, baryta carbonica, chimaphila umbellata, clematis erecta, conium maculatum, digitalis purpurea, ferrum picricum, phosphoricum acidum, sabal serrulata, selenium metallicum, staphysagria, thuja occidentalis, zincum metallicum., reference image prostate.jpg - uses a natural aid for: - prostate symptoms - burning and irritation - scanty urination - dribbling - premature impotence reference image prostate.jpg uses a natural aid for: prostate symptoms, burning and irritation, scanty urination, dribbling, premature impotence. helps to tone and strengthen the prostate gland. reference image prostate.jpg

United States - English - NLM (National Library of Medicine)

professional complementary health formulas - prostate 12x - for the temporary relief of frequent or difficult urination, a feeling of urgency to urinate, or decreased sexual desire or satisfaction.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Ireland - English - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - potassium hydrogen carbonate; sodium alginate - oral suspension - 500mg/ 5 ml+100 mg/5ml - other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)

Ireland - English - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - potassium bicarbonate; sodium alginate - chewable tablet - 500/100 milligram(s) - other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord); alginic acid

United States - English - NLM (National Library of Medicine)

roerig - penicillin g potassium (unii: vl775zth4c) (penicillin g - unii:q42t66vg0c) - penicillin g 5000000 [iu] - penicillin g potassium for injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin g. therapy with penicillin g potassium for injection, usp may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis streptococcus pyogenes (group a β-hemolytic streptococcus), other β-hemolytic streptococci including groups c, h, g, l and m, streptococcus pneumoniae and staphylococcus species (non-penicillinase producing strains) anthrax bacillus anthracis actinomycosis (cervico-facial disease and thoracic and abdominal disease) actinomyces israelii botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) clostridium species diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) corynebacterium diphtheriae erysipelothrix endocarditis erysipelothrix rhusiopathiae fusospirochetosis (severe infections of the oropharynx [vincent's], lower respiratory tract and genital area) fusobacterium species and spirochetes listeria infections including meningitis and endocarditis listeria monocytogenes pasteurella infections including bacteremia and meningitis pasteurella multocida haverhill fever streptobacillus moniliformis rat bite fever spirillum minus or streptobacillus moniliformis disseminated gonococcal infections neisseria gonorrhoeae (penicillin-susceptible) syphilis (congenital and neurosyphilis) treponema pallidum meningococcal meningitis and/or septicemia neisseria meningitidis gram-negative bacillary infections (bacteremias) penicillin g is not the drug of choice in the treatment of gram-negative bacillary infections. gram-negative bacillary organisms (i.e . enterobacteriaceae) to reduce the development of drug-resistant bacteria and maintain effectiveness of penicillin g potassium and other antibacterial drugs, penicillin g potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. a history of a hypersensitivity (anaphylactic) reaction to any penicillin is a contraindication.

United States - English - NLM (National Library of Medicine)

roerig - penicillin g potassium (unii: vl775zth4c) (penicillin g - unii:q42t66vg0c) - penicillin g 5000000 [iu] - penicillin g potassium for injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin g. therapy with penicillin g potassium for injection, usp may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis streptococcus pyogenes (group a β-hemolytic streptococcus), other β-hemolytic streptococci including groups c, h, g, l and m, streptococcus pneumoniae and staphylococcus species (non-penicillinase producing strains) anthrax bacillus anthracis actinomycosis (cervico-facial disease and thoracic and abdominal disease) actinomyces israelii botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) clostridium species diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) corynebacterium diphtheriae erysipelothrix endocarditis erysipelothrix rhusiopathiae fusospirochetosis (severe infections of the oropharynx [vincent's], lower respiratory tract and genital area) fusobacterium species and spirochetes listeria infections including meningitis and endocarditis listeria monocytogenes pasteurella infections including bacteremia and meningitis pasteurella multocida haverhill fever streptobacillus moniliformis rat bite fever spirillum minus or streptobacillus moniliformis disseminated gonococcal infections neisseria gonorrhoeae (penicillin-susceptible) syphilis (congenital and neurosyphilis) treponema pallidum meningococcal meningitis and/or septicemia neisseria meningitidis gram-negative bacillary infections (bacteremias) penicillin g is not the drug of choice in the treatment of gram-negative bacillary infections. gram-negative bacillary organisms (i.e . enterobacteriaceae) to reduce the development of drug-resistant bacteria and maintain effectiveness of penicillin g potassium and other antibacterial drugs, penicillin g potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. a history of a hypersensitivity (anaphylactic) reaction to any penicillin is a contraindication.